Immune Design Corp (NASDAQ:IMDZ) EVP Stephen R. Brady sold 3,328 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.17, for a total value of $13,877.76. Following the sale, the executive vice president now owns 50,490 shares of the company’s stock, valued at $210,543.30. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Immune Design Corp (NASDAQ:IMDZ) opened at $3.92 on Tuesday. Immune Design Corp has a 1 year low of $3.50 and a 1 year high of $13.05. The firm has a market capitalization of $188.63, a price-to-earnings ratio of -1.84 and a beta of 2.36.
Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.11. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.62 million. equities analysts forecast that Immune Design Corp will post -1.89 EPS for the current year.
Hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers raised its position in Immune Design by 53.9% in the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 6,896 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Immune Design in the second quarter valued at about $117,000. Bank of New York Mellon Corp raised its position in Immune Design by 28.5% in the second quarter. Bank of New York Mellon Corp now owns 79,211 shares of the biotechnology company’s stock valued at $773,000 after purchasing an additional 17,563 shares during the last quarter. JPMorgan Chase & Co. raised its position in Immune Design by 118.7% in the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock valued at $5,175,000 after purchasing an additional 288,009 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in Immune Design by 2.7% in the second quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock valued at $7,412,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 29.34% of the company’s stock.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
What are top analysts saying about Immune Design? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immune Design and related companies.